Skip to main content
. Author manuscript; available in PMC: 2015 Apr 22.
Published in final edited form as: J Patient Cent Res Rev. 2014 Spring;1(2):85–92. doi: 10.17294/2330-0698.1017

Table 3.

Median progression-free survival (PFS) values for CTC-positive and CTC-negative patients, and Cox proportional hazard ratios (HR) based on univariate analysis.

Author Year Median PFS CTC<5, CTC =>5 (Month) 95% CI CTC<5, CTC=>5 PFS (Month) Cox HR
Cristofanilli27 2004 7.0, 2.7 (5.8–8.9), (2.1–4.4) 1.76
Nole41 2008 >11.5, 5.1 N/A 2.5
Liu34 2009 5.1, 3.2 (3.1–6.7), (2.5–6.2) 1.4
Gradilone54 2011 16.3, 9.2 N/A N/A
Giuliano33 2011 12.0, 7.0 (9.6–14.3), (5.8–8.2) 1.72
Muller76 2011 10.9, 9.3 (9.4–12.5), (7.8–10.9) N/A
Pierga80 2012 16.0, 8.2 N/A 1.9
Giordano77 2012 6.3, 5.8 (5.3–7.3), (5.0–6.7) 1.23
Wallwiener79 2013 7.6, 4.8 (5.9–9.3), (3.9–5.6) 1.82

CTC: circulating tumor cell; CI: confidence interval.